$1.12
1.75% yesterday
Nasdaq, Sep 26, 10:00 pm CET
ISIN
US00534A1025
Symbol
IVVD

Adagio Therapeutics Inc Stock price

$1.12
+0.09 8.74% 1M
+0.50 81.97% 6M
+0.68 152.76% YTD
+0.08 7.69% 1Y
-2.04 64.56% 3Y
-15.88 93.41% 5Y
-15.88 93.41% 10Y
-15.88 93.41% 20Y
Nasdaq, Closing price Fri, Sep 26 2025
-0.02 1.75%
ISIN
US00534A1025
Symbol
IVVD
Industry

Key metrics

Basic
Market capitalization
$218.4m
Enterprise Value
$183.4m
Net debt
positive
Cash
$34.9m
Shares outstanding
120.1m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
4.7 | 4.1
EV/Sales
4.0 | 3.4
EV/FCF
negative
P/B
5.1
Financial Health
Equity Ratio
52.2%
Return on Equity
-251.6%
ROCE
-254.0%
ROIC
-313.9%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$46.2m | $53.9m
EBITDA
$-110.2m | $-22.5m
EBIT
$-113.5m | $-58.2m
Net Income
$-110.1m | $-47.2m
Free Cash Flow
$-113.3m
Growth (TTM | estimate)
Revenue
1,944.7% | 112.4%
EBITDA
48.6% | 87.0%
EBIT
47.4% | 67.1%
Net Income
46.0% | 72.2%
Free Cash Flow
39.3%
Margin (TTM | estimate)
Gross
93.4%
EBITDA
-238.5% | -41.8%
EBIT
-245.7%
Net
-238.3% | -87.5%
Free Cash Flow
-245.1%
More
EPS
$-0.9
FCF per Share
$-0.9
Short interest
4.5%
Employees
100
Rev per Employee
$250.0k
Show more

Is Adagio Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,008 stocks worldwide.

Adagio Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Adagio Therapeutics Inc forecast:

7x Buy
88%
1x Hold
13%

Analyst Opinions

8 Analysts have issued a Adagio Therapeutics Inc forecast:

Buy
88%
Hold
13%

Financial data from Adagio Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
46 46
1,945% 1,945%
100%
- Direct Costs 3.05 3.05
3,289% 3,289%
7%
43 43
1,880% 1,880%
93%
- Selling and Administrative Expenses 61 61
5% 5%
131%
- Research and Development Expense 96 96
38% 38%
208%
-110 -110
49% 49%
-238%
- Depreciation and Amortization 3.32 3.32
159% 159%
7%
EBIT (Operating Income) EBIT -114 -114
47% 47%
-246%
Net Profit -110 -110
46% 46%
-238%

In millions USD.

Don't miss a Thing! We will send you all news about Adagio Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Adagio Therapeutics Inc Stock News

Neutral
GlobeNewsWire
3 days ago
NEW HAVEN, Conn., Sept. 24, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (NASDAQ: IVVD) today announced the appointment of Paul B. Bolno, M.D., to its Board of Directors and as a member of the Compensation Committee. Dr. Bolno is the President and CEO of Wave Life Sciences, a clinical-stage biotechnology company, and has served in those roles since 2013.
Neutral
GlobeNewsWire
10 days ago
NEW HAVEN, Conn., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced the appointment of Kristie Kuhl as Chief Communications Officer. Ms. Kuhl will lead the Company's communications and patient advocacy efforts as Invivyd advances its mission of providing monoclonal antibodies for the prevention and treatment of viral disease.
Neutral
GlobeNewsWire
23 days ago
WALTHAM, Mass., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) today announced that the SPEAR Study Group has issued their consensus recommendation for a clinical study design to evaluate the effects of monoclonal antibody (mAb) therapy on Long COVID. The recommendation will be presented for consideration to RECOVER-TLC, an NIH initiative devoted to testing potential treatments...
More Adagio Therapeutics Inc News

Company Profile

Adagio Therapeutics, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers, ADG20, a monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren? Russo and Laura Walker on June 3, 2020 and is headquartered in Waltham, MA.

Head office United States
CEO William Duke
Employees 100
Founded 2020
Website invivyd.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today